Key result
The niMON trial evaluates if continuous versus intermittent non-invasive blood pressure monitoring reduces postoperative MINS.
Why the study?
Whether continuous noninvasive blood pressure monitoring during the intraoperative period improves patient outcomes compared with intermittent monitoring is unclear.
Does continuous noninvasive blood pressure monitoring reduce postoperative myocardial injury in surgical patients compared to intermittent monitoring?
Does continuous noninvasive blood pressure monitoring reduce postoperative myocardial injury in surgical patients compared to intermittent monitoring?
The niMON trial protocol outlines a randomized study to determine if continuous intraoperative noninvasive blood pressure monitoring improves postoperative outcomes compared to intermittent monitoring.
Answers are grounded in this paper and cite their sources.
Continuous BP monitoring may enable earlier hypotension treatment perioperatively; leaves open whether it reduces postoperative organ injury.
BACKGROUND: Blood pressure has become one of the most important vital signs to monitor in the perioperative setting. Recently, the Italian Society of Anesthesia Analgesia Resuscitation and Intensive Care (SIAARTI) recommended, with low level of evidence, continuous monitoring of blood pressure during the intraoperative period. Continuous monitoring allows for early detection of hypotension, which may potentially lead to a timely treatment. Whether the ability to detect more hypotension events by continuous noninvasive blood pressure (C-NiBP) monitoring can improve patient outcomes is still unclear. Here, we report the rationale, study design, and statistical analysis plan of the niMON trial, which aims to evaluate the effect of intraoperative C-NiBP compared with intermittent (I-NiBP) monitoring on postoperative myocardial and renal injury. METHODS: The niMon trial is an investigator-initiated, multicenter, international, open-label, parallel-group, randomized clinical trial. Eligible patients will be randomized in a 1:1 ratio to receive C-NiBP or I-NiBP as an intraoperative monitoring strategy. The proportion of patients who develop myocardial injury in the first postoperative week is the primary outcome; the secondary outcomes are the proportions of patients who develop postoperative AKI, in-hospital mortality rate, and 30 and 90 postoperative days events. A sample size of 1265 patients will provide a power of 80% to detect a 4% absolute reduction in the rate of the primary outcome. CONCLUSIONS: The niMON data will provide evidence to guide the choice of the most appropriate intraoperative blood pressure monitoring strategy. CLINICAL TRIAL REGISTRATION: of August 2023.
No takes yet. Share an insight, caveat, or question.
Noto et al. (2024) studied Elective noncardiac surgery (n=1,265). Continuous non-invasive blood pressure (C-NiBP) monitoring vs. Intermittent non-invasive blood pressure (I-NiBP) monitoring was evaluated on Proportion of patients developing myocardial injury after noncardiac surgery (MINS) in the first postoperative week. The niMON trial is a planned randomized study designed to evaluate whether continuous non-invasive blood pressure monitoring reduces postoperative myocardial injury compared to intermittent monitoring.
Synapse has enriched 10 related papers. Consider them for comparative context: